Your shopping cart is currently empty

Ginkgolide B (BN-52021) is a PAFR antagonist(IC50=3.6 μM) isolated from Ginkgo biloba.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 5 mg | $30 | In Stock | In Stock | |
| 10 mg | $37 | In Stock | In Stock | |
| 25 mg | $57 | In Stock | In Stock | |
| 50 mg | $97 | In Stock | In Stock | |
| 100 mg | $138 | In Stock | In Stock | |
| 500 mg | $345 | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $63 | In Stock | In Stock |
| Description | Ginkgolide B (BN-52021) is a PAFR antagonist(IC50=3.6 μM) isolated from Ginkgo biloba. |
| Targets&IC50 | PAF receptor:3.6 μM |
| In vitro | Oral administration of Ginkgolide B (50 mg/kg) before ischemia notably reduces neuronal damage in the hippocampus of rats. In a mouse model of focal transient ischemia, a 30-minute pretreatment with Ginkgolide B (100 mg/kg, s.c.) diminishes the area of infarction. Additionally, in animals anesthetized with pentobarbital or ethyl carbamate, Ginkgolide B, administered either intravenously (1 mg/kg) or orally (10 mg/kg), inhibits bronchoconstriction and increases hematocrit. |
| In vivo | Ginkgolide B effectively inhibits platelet-activating factor (PAF) receptors. In cystic cells, it modifies the Ras/MAPK signaling pathway, inducing cell differentiation. In EPC cells, Ginkgolide B promotes cell proliferation and endothelial gene expression by inducing the phosphorylation of eNOS, Akt, and p38, significantly enhancing vascular endothelial growth factor (VEGF)-induced migration responses. |
| Synonyms | BN-52021 |
| Molecular Weight | 424.40 |
| Formula | C20H24O10 |
| Cas No. | 15291-77-7 |
| Smiles | CC1C(=O)OC2C(O)C34C5CC(C(C)(C)C)C33C(O)C(=O)OC3OC4(C(=O)O5)C12O |
| Relative Density. | 1.64 g/cm3 |
| Storage | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 125.00 mg/mL (294.53 mM), Sonication is recommended. Ethanol: 10.60 mg/mL (24.98 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2.00 mg/mL (4.71 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||||||||||||
Ethanol/DMSO
DMSO
| |||||||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.